IP Library › Granted Patent US 12,485,180
Granted Patent B2
US 12,485,180 · App. 17/638,642 · Granted Dec 2, 2025

Compositions and methods for delivery of nucleic acids to cells

Inventors: Elias Quijano (Durham, CT); Peter Glazer (Guilford, CT)
Assignee: Yale University
A61K47/549A61K47/6807A61K47/6851A61K48/0025A61K48/005A61P35/00C07K14/4747C07K14/52C07K16/44C12N15/111C12N15/113C12N15/1135C12N15/87A61K2039/505A61K48/00C07K2317/24C07K2317/31C07K2317/565C07K2317/622C07K2317/77C07K2319/33C12N2310/11C12N2310/14C12N2310/3181C12N2310/3513C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,485,180
App. No.
17/638,642
Granted
Dec 2, 2025
Kind
B2
Abstract

Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.

Claims (13)

1 . A method of delivering a nucleic acid cargo to a cell comprising contacting the cell with an effective amount of a composition comprising a non-covalent complex of:

(a) an antibody or an antigen-binding fragment thereof, or a humanized antibody, or an antigen-binding fragment thereof, comprising

heavy chain variable region (VH) complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18; and light chain variable region (VL) CDRs comprising the amino acid sequences of SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO:26;

and

(b) a nucleic acid cargo selected from the group consisting of a DNA, an RNA, a PNA, a plasmid, a C polynucleotide encoding a Cas endonuclease.

2 . The method of claim 1 , wherein (a) targets a cell type of interest.

3 . The method of claim 1 , wherein the RNA comprises mRNA a gRNA, an antisense molecule, an siRNA, a miRNA, a RNAi, an external guide sequence, or an aptamer.

4 . The method of claim 1 , wherein the DNA comprises a vector.

5 . The method of claim 4 , wherein the vector comprises a nucleic acid sequence encoding a polypeptide operably linked to an expression control sequence.

6 . The method of claim 1 , wherein the composition further comprises carrier DNA.

7 . The method of claim 6 , wherein the carrier DNA is non-coding DNA.

8 . The method of claim 1 , wherein the contacting occurs in vivo following administration to a subject in need thereof.

9 . The method of claim 1 , wherein the DNA is an oligonucleotide ligand.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2022
From: QUIJANO, ELIAS; GLAZER, PETER
To: YALE UNIVERSITY
Reel/Frame 060931/0376 →
Continuity (4)
Continuation In Part PCTUS2019048953 · Aug 30, 2019
Continuation In Part PCTUS2019048962 · Aug 30, 2019
Provisional Application 62944281 · Dec 5, 2019
Related Publication 20230227583A1 · Jul 20, 2023
References Cited (400)
US 4714680A · Civin · 1987 [cited by applicant]
US 4812397A · Weisbart · 1989 [cited by applicant]
US 4965204A · Civin · 1990 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5061620A · Tsukamoto et al. · 1991 [cited by applicant]
US 5075109A · Tice et al. · 1991 [cited by applicant]
US 5142047A · Summmerton et al. · 1992 [cited by applicant]
US 5166315A · Summerton et al. · 1992 [cited by applicant]
US 5217866A · Summerton et al. · 1993 [cited by applicant]
US 5356802A · Chandrasegaran · 1994 [cited by applicant]
US 5422251A · Fresco · 1995 [cited by applicant]
US 5436150A · Chandrasegaran · 1995 [cited by applicant]
US 5487994A · Chandrasegaran · 1996 [cited by applicant]
US 5506337A · Summerton et al. · 1996 [cited by applicant]
US 5521063A · Summerton et al. · 1996 [cited by applicant]
US 5527675A · Coull et al. · 1996 [cited by applicant]
US 5539082A · Nielsen et al. · 1996 [cited by applicant]
US 5623049A · Löbberding et al. · 1997 [cited by applicant]
US 5643741A · Tsukamoto et al. · 1997 [cited by applicant]
US 5677136A · Simmons et al. · 1997 [cited by applicant]
US 5698685A · Summerton · 1997 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5716827A · Tsukamoto et al. · 1998 [cited by applicant]
US 5736336A · Buchardt et al. · 1998 [cited by applicant]
US 5750397A · Tsukamoto et al. · 1998 [cited by applicant]
US 5759793A · Schwartz et al. · 1998 [cited by applicant]
US 5773571A · Nielsen et al. · 1998 [cited by applicant]
US 5786571A · Bethel et al. · 1998 [cited by applicant]
US 5945337A · Brown · 1999 [cited by applicant]
US 5962426A · Glazer · 1999 [cited by applicant]
US 6140081A · Barbas · 2000 [cited by applicant]
US 6261841B1 · Cohen et al. · 2001 [cited by applicant]
US 6303376B1 · Glazer · 2001 [cited by applicant]
US 6326479B1 · Gildea et al. · 2001 [cited by applicant]
US 6441130B1 · Egholm et al. · 2002 [cited by applicant]
US 6453242B1 · Eisenberg et al. · 2002 [cited by applicant]
US 6534261B1 · Cox, III et al. · 2003 [cited by applicant]
US 6610512B1 · Barbas · 2003 [cited by applicant]
US 6746838B1 · Choo et al. · 2004 [cited by applicant]
US 6866997B1 · Choo et al. · 2005 [cited by applicant]
US 6919208B2 · Levy et al. · 2005 [cited by applicant]
US 7067617B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7078389B2 · Glazer et al. · 2006 [cited by applicant]
US 7189396B1 · Weisbart · 2007 [cited by applicant]
US 7279463B2 · Glazer · 2007 [cited by applicant]
US 8309356B2 · Glazer · 2012 [cited by applicant]
US 8658608B2 · Glazer et al. · 2014 [cited by applicant]
US 8834866B2 · Armstrong · 2014 [cited by applicant]
US 9193758B2 · Ly et al. · 2015 [cited by applicant]
US 9447394B2 · Armstrong · 2016 [cited by applicant]
US RE46211E · Weisbart · 2016 [cited by examiner]
US 9610362B2 · Armstrong · 2017 [cited by applicant]
US 9732146B2 · Nishimura et al. · 2017 [cited by applicant]
US 10017581B2 · Armstrong et al. · 2018 [cited by applicant]
US 10202591B2 · Armstrong · 2019 [cited by applicant]
US 10221250B2 · Armstrong et al. · 2019 [cited by applicant]
US 10238753B2 · Armstrong · 2019 [cited by applicant]
US 10501554B2 · Armstrong · 2019 [cited by applicant]
US 11136597B2 · Saltzman et al. · 2021 [cited by applicant]
US 11590242B2 · Zhou et al. · 2023 [cited by applicant]
US 11850284B2 · Quijano et al. · 2023 [cited by applicant]
US 11872286B2 · Quijano et al. · 2024 [cited by applicant]
US 12005121B2 · Quijano et al. · 2024 [cited by applicant]
US 20020165356A1 · Barbas, III et al. · 2002 [cited by applicant]
US 20030003100A1 · Levy et al. · 2003 [cited by applicant]
US 20030148352A1 · Glazer · 2003 [cited by applicant]
US 20040197892A1 · Moore et al. · 2004 [cited by applicant]
US 20070036773A1 · Cooper · 2007 [cited by examiner]
US 20070154989A1 · Barbas, III · 2007 [cited by applicant]
US 20070213269A1 · Barbas, III et al. · 2007 [cited by applicant]
US 20100111977A1 · Armstrong · 2010 [cited by examiner]
US 20100172882A1 · Glazer et al. · 2010 [cited by applicant]
US 20110145940A1 · Voytas et al. · 2011 [cited by applicant]
US 20110262406A1 · Del Campo et al. · 2011 [cited by applicant]
US 20110268810A1 · Saltzman et al. · 2011 [cited by applicant]
US 20110293585A1 · Del Campo et al. · 2011 [cited by applicant]
US 20130071414A1 · Dotti et al. · 2013 [cited by applicant]
US 20130266570A1 · Weisbart · 2013 [cited by applicant]
US 20140050709A1 · Leen et al. · 2014 [cited by applicant]
US 20140342003A1 · Saltzman et al. · 2014 [cited by applicant]
US 20150017120A1 · Wittrup et al. · 2015 [cited by applicant]
US 20150283178A1 · June et al. · 2015 [cited by applicant]
US 20150290244A1 · June et al. · 2015 [cited by applicant]
US 20170281795A1 · Geall et al. · 2017 [cited by applicant]
US 20170283830A1 · Saltzman et al. · 2017 [cited by applicant]
US 20190247515A1 · Zhou et al. · 2019 [cited by applicant]
US 20210338815A1 · Quijano et al. · 2021 [cited by applicant]
US 20210340280A1 · Quijano et al. · 2021 [cited by applicant]
US 20230032060A1 · Quijano et al. · 2023 [cited by applicant]
US 20230085308A1 · Quijano et al. · 2023 [cited by applicant]
US 20230093460A1 · Quijano et al. · 2023 [cited by applicant]
US 20230093888A1 · Quijano et al. · 2023 [cited by applicant]
US 20230227583A1 · Quijano et al. · 2023 [cited by applicant]
US 20230265214A1 · Quijano et al. · 2023 [cited by applicant]
US 20230272115A1 · Quijano et al. · 2023 [cited by applicant]
US 20230277658A1 · Quijano et al. · 2023 [cited by applicant]
US 20230303719A1 · Quijano et al. · 2023 [cited by applicant]
US 20240190998A1 · Quijano et al. · 2024 [cited by applicant]
US 20240285774A1 · Quijano et al. · 2024 [cited by applicant]
US 20240285775A1 · Quijano et al. · 2024 [cited by applicant]
CN 1986792A · 2007 [cited by applicant]
CN 111218458A · 2020 [cited by applicant]
JP 2010527618A · 2010 [cited by applicant]
JP 2017509328A · 2017 [cited by applicant]
WO WO9501364A1 · 1995 [cited by applicant]
WO WO9639195A2 · 1996 [cited by applicant]
WO WO9640271A1 · 1996 [cited by applicant]
WO WO9640898A1 · 1996 [cited by applicant]
WO WO1997032602A1 · 1997 [cited by applicant]
WO WO199853059A1 · 1998 [cited by applicant]
WO WO200244321A2 · 2002 [cited by applicant]
WO WO2003016496A2 · 2003 [cited by applicant]
WO WO03052071A2 · 2003 [cited by applicant]
WO WO2006024518A1 · 2006 [cited by applicant]
WO WO2008086529A2 · 2008 [cited by applicant]
WO WO2008091911A2 · 2008 [cited by applicant]
WO WO2008148063A1 · 2008 [cited by applicant]
WO WO2010123983A1 · 2010 [cited by applicant]
WO WO2010138769A1 · 2010 [cited by examiner]
WO WO2011053989A2 · 2011 [cited by applicant]
WO WO2011072246A2 · 2011 [cited by applicant]
WO WO2011133802A1 · 2011 [cited by applicant]
WO WO2011133803A1 · 2011 [cited by applicant]
WO WO2012135831A1 · 2012 [cited by applicant]
WO WO2013082529A1 · 2013 [cited by applicant]
WO WO2013138662A1 · 2013 [cited by applicant]
WO WO2013176772A1 · 2013 [cited by applicant]
WO WO2014018423A2 · 2014 [cited by applicant]
WO WO2015106290A1 · 2015 [cited by examiner]
WO WO2015134607A1 · 2015 [cited by applicant]
WO WO2015143177A1 · 2015 [cited by applicant]
WO WO2016033321A1 · 2016 [cited by applicant]
WO WO2016033324A1 · 2016 [cited by applicant]
WO WO2016081621A1 · 2016 [cited by applicant]
WO WO2017015101A1 · 2017 [cited by applicant]
WO WO2017015630A2 · 2017 [cited by applicant]
WO WO2017109177A1 · 2017 [cited by applicant]
WO WO2017143042A2 · 2017 [cited by applicant]
WO WO2017143061A1 · 2017 [cited by applicant]
WO WO2017218825A1 · 2017 [cited by examiner]
WO WO2018187493A1 · 2018 [cited by applicant]
WO WO2019018426A1 · 2019 [cited by applicant]
WO WO2019018428A1 · 2019 [cited by applicant]
WO WO2019079215A1 · 2019 [cited by applicant]
WO WO2019152806A1 · 2019 [cited by applicant]
WO WO2019152808A1 · 2019 [cited by applicant]
WO WO2020047344A1 · 2020 [cited by applicant]
WO WO2020047353A1 · 2020 [cited by applicant]
WO WO2020128146A1 · 2020 [cited by applicant]
WO WO2021042060A1 · 2021 [cited by applicant]
Pradhan et al., Cytotechnology 64: 613-622 (Year: 2012). [cited by examiner]
Weisbart et al., Journal of Immunology 144: 2653-2658 (Year: 1990). [cited by examiner]
Rudikoff et al., Proc Natl Acad Sci USA vol. 79 p. 1979 (Year: 1982). [cited by examiner]
Piche-Nicholas et al MABS 10(1): 81-94 (Year: 2018). [cited by examiner]
Wu et al., J Mol Biol 294: 151-162 (Year: 1999). [cited by examiner]
Ahmed, N., et al., “Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression,” Mol. Ther. 17:1779-1787, Cell Press, United States (2009). [cited by applicant]
Ahmed, N., et al., “HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors,” Clin. Cancer Res. 16:474-485, American Association for Cancer Research, United S… [cited by applicant]
Altenschmidt, U., et al., “Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes,” Clin. Cancer Res. 2:1001-1008, American Association for Cancer Re… [cited by applicant]
Ansell, S.M., et al., “PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma,” The New England Journal of Medicine 372:311-319, Massachusetts Medical Society, United States (2015). [cited by applicant]
Azuma, T., et al., “B7—H1 is a ubiquitous antiapoptotic receptor on cancer cells,” Blood 111:3635-3642, American Society of Hematology, United States (2008). [cited by applicant]
Baldwin, S.A., et al., “The equilibrative nucleoside transporter family, SLC29,” Pflugers Arch. 447(5):753-743, Springer Verlag, Germany (2004). [cited by applicant]
Barber, A., et al., “Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma,” Exp. Hematol. 36:1318-1328, Elsevier, Netherlands (2008). [cited by applicant]
Barrett, D.M., et al., “Chimeric antigen receptor therapy for cancer,” Annu. Rev. Med. 65:333-347, Annual Reviews, United States (2014). [cited by applicant]
Berger, C., et al., “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,” J. Clin. Invest 118:294-305, American Society for Clinical Investigati… [cited by applicant]
Bernstein, E., et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference,” Nature 409:363-369, Nature Portfolio, Germany (2001). [cited by applicant]
Bodera, P., “Immunostimulatory oligonucleotides,” Recent Pat. Inflamm. Allergy Drug Discov. 5:87-93, Bentham Science Publishers B.V, United Arab Emirates (2011). [cited by applicant]
Braasch, D. A., and Corey, D. R., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA,” Chem Biol 8(1):1-7, Cell Press, United States (Jan. 2001). [cited by applicant]
Brahmer, J.R., et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” J. Clin. Oncol. 28:3167-3175… [cited by applicant]
Brentjens, R.J., “Cellular therapies in acute lymphoblastic leukemia,” Curr. Opin. Mol Ther. 11(4):375-382, Elsevier, Netherlands (2009). [cited by applicant]
Brentjens, R.J., et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Sci. Transl. Med. 5:177ra38, American Association for the Advance… [cited by applicant]
Brentjens, R.J., et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” Nat. Med. 9:279-286, Nature Portfolio, Germany (2003). [cited by applicant]
Brentjens, R.J., et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood 118:4817-4828, American Society o… [cited by applicant]
Brown, C.E., et al., “Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells,” Clin Cancer Res 18(8):2199-2209, American Association for Can… [cited by applicant]
Bullain, S.S., et al. “Genetically engineered T cells to target EGFRvIII expressing glioblastoma,” J. Neurooncol. 94(3):373-382, Springer, Germany (2009). [cited by applicant]
Burns, W.R., et al., “A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas,” Cancer Res 70:3027-3033, American Association for Cancer Res… [cited by applicant]
Butte, M.J., et al., “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses,” Immunity 27:111-122, Cell Press, United States (2007). [cited by applicant]
Carreno, B.M., et al., “The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses,” Annu. Rev. Immunol. 20:29-53, Annual Reviews, United States (2002). [cited by applicant]
Cartellieri, M., et al., “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer,” J. Biomed. Biotechnol. 2010:956304, Hindawi, United Kingdom (2010). [cited by applicant]
Cermak, T., et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting,” Nucleic Acids Res 39(12):e82, 11 pages, Oxford University Press, United Kingdom (Jul. 2011). [cited by applicant]
Charo, J., et al., “Bcl-2 overexpression enhances tumor-specific T-cell survival,” Cancer Res. 65(5):2001-2008, American Association for Cancer Research, United States (2005). [cited by applicant]
Cheever, M.A., et al., “The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research,” Clin Cancer Res. 15:5323-5337, American Association for Cancer Re… [cited by applicant]
Chen, L., “Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,” Nat. Rev. Immunol. 4:336-347, Nature Portfolio, Germany (2004). [cited by applicant]
Chen, L., et al., “Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future,” J. Clin. Invest. 125:3384-3391, American Society for Clinical Investigation, United States (2015). [cited by applicant]
Chen, Z., et al., “A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors,” Oncotarget. 7(37):59965-59975, Impact Journals, United States (2016). [cited by applicant]
Cheung, N.K., et al., “Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy,” Hybrid Hybridomics 22:209-218, Mary Ann Liebert, I… [cited by applicant]
Chinnasamy, D., et al., “Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice,” J. Clin. Invest. 120:3953-3968, American Society for Clinical … [cited by applicant]
Chmielewski, M., et al., “T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target … [cited by applicant]
Chothia, C., and Lesk, A. M., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol 196(4):901-917, Elsevier Science, United States (Aug. 1987). [cited by applicant]
Chow, K.M., et al., “T cells redirected to EphA2 for the immunotherapy of glioblastoma,” Mol. Ther. 21:629-637, Cell Press, United States (2013). [cited by applicant]
Cong, L., “Multiplex genome engineering using CRISPR/Cas systems,” Science 339(6121):819-823, American Association for the Advancement of Science, United States (Feb. 2013). [cited by applicant]
Cooper, L., et al., “Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1,” Blood 105:1622-1631, American Society of Hematology, United… [cited by applicant]
Cougot, N., et al., “‘Cap-tabolism’,” Trends. Biochem. Sci. 29:436-444, Elsevier, Netherlands (2001). [cited by applicant]
Crawford, C.R., et al., “Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line,” J. Biol. Chem. … [cited by applicant]
Curran, K.J., et al., “Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions,” J. Gene. Med. 14:405-415, John Wiley & Sons, United States (2012). [cited by applicant]
Dall, P., et al., “In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells,” Cancer Immunol. Immunother. 54:51-60, Springer Science+Business Media, Germany (2005). [cited by applicant]
Dalpke, A.H., et al., “Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo,” Im… [cited by applicant]
Daly, T., et al., “Recognition of human colon cancer by T cells transduced with a chimeric receptor gene,” Cancer Gene Ther. 7:284-291, Springer Nature, United Kingdom (2000). [cited by applicant]
Danial, N.N., et al., “Cell death: critical control points,” Cell 116:205-219, Cell Press, United States (2004). [cited by applicant]
Davies, D.M., et al., “Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells,” Mol Med. 18:565-576, The Feinstein Institutes for Medical Research, United States (2012). [cited by applicant]
Desai, M. P., et al., “The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent,” Pharm Res 14(11):1568-1573, Springer Science+Business Media, Germany (Nov. 1997). [cited by applicant]
Di Stasi. A., et al., “T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model” Blood 113:6392-6402, American Society of Hemato… [cited by applicant]
Dong, H., et al., “B7—H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes,” Immunity 20:327-336, Cell Press, United States (2004). [cited by applicant]
Dotti, G., “The other face of chimeric antigen receptors,” Mol. Ther. 22(5):899-890, Cell Press, United States (2014). [cited by applicant]
Dotti, G., et al., “Design and development of therapies using chimeric antigen receptor-expressing T cells,” Immunol. Rev.257: 107-126, John Wiley & Sons Ltd, United States (2014). [cited by applicant]
Eaton, D., et al., “Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions,” Gene Therapy 9:527-535, Springer Nature, United Kingdom… [cited by applicant]
Elango, N., et al., “Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector,” Biochem. Biophys. Res. Commun. 330:958-966, Elsevier, Netherlands (2005). [cited by applicant]
Elbashir, S.M., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature 411:494-498, Nature Portfolio, Germany (2001). [cited by applicant]
Elbashir, S.M., et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs,”Genes Dev. 15:188-200, Cold Spring Harbor Laboratory Press, United States (2001). [cited by applicant]
Federov, V.D., et al., “PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses,” Science Translational Medicine 5:215ra172, American Association for the Advancemen… [cited by applicant]
Finney, H.M., et al., “Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product,” J. Immunol. 161:2791-2797, American Association of Immunologists, United States (1998). [cited by applicant]
Fire, A., et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature 391:806-811, Nature Portfolio, Germany (1998). [cited by applicant]
Flies, D.B., et al., “The new B7s: playing a pivotal role in tumor immunity,” J. Immunotherapy 30:251-260, Lippincott Williams and Wilkins Ltd., United States (2007). [cited by applicant]
Gattenlohner, S., et al., “Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor,” Cancer Res. 66:24-28, American Association for Cancer Res… [cited by applicant]
Gattinoni, L., et al., “A human memory T cell subset with stem cell-like properties,” Nat. Med. 17:1290-1297, Nature Portfolio, Germany (2011). [cited by applicant]
Genbank, “immunoglobulin heavy chain, partial [Mus musculus],” ncbi.nlm.nih.gov, Accession No. AAA65679.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/protein/AAA65679] on Jan. 14, 2022, 1 page. [cited by applicant]
Gilham, D.E., et al., “Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors,” J. Immunother. 25:139-15… [cited by applicant]
Gong, M.C., et al., “Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen,” Ne… [cited by applicant]
Govindarajan, R., et al., “In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta,” Am. J. Physiol. Regul. Integr. Co… [cited by applicant]
Grada, Z., et al., “TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy,” Mol. Ther. Nucleic Acids 2:e105, Elsevier, Netherlands (2013). [cited by applicant]
Greenwald, R.J., et al., “The B7 family revisited,” Annu. Rev. Immunol. 23:515-548, Annual Reviews, United States (2005). [cited by applicant]
Griffiths, M., et al., “Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta,” Biochem. J. 328(3):739-743, Portland Press, United K… [cited by applicant]
Grupp, S.A., et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” N. Engl. J. Med 368(16):1509-1518, Massachusetts Medical Society, United States (2013). [cited by applicant]
Hamid, O., et al., “A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma,” J. Transl. Med. 9:204, BioMed Central, Unit… [cited by applicant]
Hammond, S.M., et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing in [cited by applicant]
Hanna, J., et al., “Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin,” Science 318(5858):1920-1923, American Association for the Advancement of Science, United States (Dec. 2007). [cited by applicant]
Hannon, G.J., “RNA interference,” Nature 418:244-251, Nature Portfolio, Germany (2002). [cited by applicant]
Hansen, J.E., et al., “Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo,” Cancer Res. 67(4):1769-1774, American Association for Cancer Research, United States (2007). [cited by applicant]
Hansen, J.E., et al., “Targeting cancer with a lupus autoantibody,” Sci. Transl. Med. 4(157):157, American Association for the Advancement of Science, United States (2012). [cited by applicant]
Hansen, J.E., et al., “Antibody-mediated Hsp70 protein therapy,” Brain. Res. 1088:187-196, Elsevier, Netherlands (2006). [cited by applicant]
Hansen, J.E., et al., “Intranuclear protein transduction through a nucleoside salvage pathway,” J. Biol. Chem. 282(29):20790-20793, American Society for Biochemistry and Molecular Biology, United States (2007). [cited by applicant]
Hartmann, G., et al., “Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo,” J. Immunol. 164(3):1617-1620, American Association of Immunologists, Unite… [cited by applicant]
Haso, W., et al., “Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia,” Blood 121:1165-1174, American Society of Hematology, United States (2013). [cited by applicant]
Haynes, N.M., et al., “Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma,” J. Immunol. 166:182-187, American A… [cited by applicant]
Heemskerk, B., et al., “Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2,” Human Gene Therapy 19:496-510, Mary Ann Liebert, Inc., Uni… [cited by applicant]
Hekele, A., et al., “Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera,” Int. J. Cancer 68:232-238, Wiley, United States (1996). [cited by applicant]
Herrmann, A., et al.,“ An effective cell-penetrating antibody delivery platform,” JCI Insight, 4(14):e127474, American Society for Clinical Investigation, United States (2019). [cited by applicant]
Hombach, A., et al., “T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition,” Gene Ther. 7:1067… [cited by applicant]
Hombach, A., et al., “An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30,” Cancer. Res. 58:1116-1119, American Associatio… [cited by applicant]
Hombach, A., et al., “T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope,” Gastroenterology 113:1163-1170, Elsevier, Netherlands (1997). [cited by applicant]
Huang, A., et al., “Functional silencing of hepatic microsomal glucose-6-phosphatase gene expression in vivo by adenovirus-mediated delivery of short hairpin RNA,” FEBS Lett 558(1-3):69-73, Wiley on behalf of FEBS, Unit… [cited by applicant]
Huang, G., et al., “Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases,” Cancer Res. 72:271-281, Am… [cited by applicant]
Hudecek, M., et al., “Receptor Affinity Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells,” Clin Cancer Res. 19(12):3153-3164, American Association for Cancer… [cited by applicant]
Hunter, M.R., et al., “Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes,” Mol. Immunol. 56:1-11, Pergamon Press, United Kingdom (2013). [cited by applicant]
Hwu, P., et al., “In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes,” Cancer Res. 55:3369-3373, American Association for Cancer Research, United States (1995). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/048823, mailed Oct. 19, 2020, European Patent Office, Germany, 14 pages. [cited by applicant]
Irving, B.A., et al., “The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways,” Cell 64:891-901, Cell Press, United States (1991). [cited by applicant]
Jensen, M., et al., “CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy,” Blood Bone Marrow Transplant 4:75-83, Elsevier, Netherlands (199… [cited by applicant]
Jensen, M.C., et al., “Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD 19-specific chimeric antigen receptor redirected T cells in humans,” Biol. Blood Marrow Tra… [cited by applicant]
Jensen, M.C., et al., “Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells,” Immunol Rev. 257:127-144, John Wiley & Sons Ltd, United States (2014). [cited by applicant]
Jinek, M., et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science 337(6096):816-821, American Association for the Advancement of Science, United States (Aug. 2012). [cited by applicant]
Kabat, E.A et al., “Sequences of proteins of immunological interest,” U.S. Dept. of Health and Human Services, United States (1991). [cited by applicant]
Kahlon, K.S., et al., “Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells,” Cancer Res. 64(24):9160-9166, American Association for Cancer Research, United… [cited by applicant]
Kakarla, S., et al., “Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma,” Mol. Ther. 21(8):1611-1620, Cell Press, United States (2013). [cited by applicant]
Kalos, M., et al., “T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia,” Sci. Transl. Med. 3:95ra73, American Association for the Advancemen… [cited by applicant]
Karlsson, H., et al., “Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy,” Cancer Gene Therapy 20:386-393, Springer Nature, United Kingdom (2013). [cited by applicant]
Katari, U.L., et al., “Engineered T cells for pancreatic cancer treatment,” HPB 13:643-650, John Wiley & Sons Inc., United Kingdom (2011). [cited by applicant]
Keir, M.E., et al., “PD-1 and its ligands in tolerance and immunity,” Annu. Rev. Immunol. 26:677-704, Annual Reviews, United States (2008). [cited by applicant]
Kershaw, M.H., et al., “A phase I study on adoptive immunotherapy using gene-modified Tcells for ovarian cancer,” Clin. Cancer Res. 12:6106-6115, American Association for Cancer Research, United States (2006). [cited by applicant]
Kershaw, M.H., et al., “Dual-specific T cells combine proliferation and antitumor activity,” Nat. Biotechnol. 20:1221-1227, Springer Nature Ltd., Germany (2002). [cited by applicant]
Kim, Y-G., and Chandrasegaran, S., “Chimeric restriction endonuclease,” Proc. Natl. Acad. Sci. USA 91(3):883-887, National Academy of Sciences, United States (Feb. 1994). [cited by applicant]
Kim, Y-G., et al., “Insertion and deletion mutants of FokI restriction endonuclease,” J. Biol. Chem. 269(50):31978-31982, Elsevier, Netherlands (Dec. 1994). [cited by applicant]
Kochenderfer, J.N., et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD 19 chimeric-antigen-receptor-transduced T cells,” Blood 119:2709-2720, Am… [cited by applicant]
Kong, S., et al., “Suppression of human glioma xenografts with second-generation IL13R- specific chimeric antigen receptor-modified T cells,” Clin Cancer Res 18:5949-5969, American Association for Cancer Research, Unite… [cited by applicant]
Kuwana, Y., et al., “Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions,” Biochem. Piophys. Res. Commun. 149:960-968, Elsevier, Netherlands (1987). [cited by applicant]
Lamers, C.H., et al., “Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience,” J. Clin. Oncol. 24(13):e20-e22, America… [cited by applicant]
Lanitis, E., et al., “Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor,” Mol. Ther. 20:633-643, Cell Press, United States (2012). [cited by applicant]
Larkin, J., et al., “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma,” The New England Journal of Medicine 373:311-319, Massachusetts Medical Society, United States (2015). [cited by applicant]
Larson, M.H., et al., “CRISPR interference (CRISPRi) for sequence-specific control of gene expression,” Nat. Protoc. 8:2180-2196, Nature Portfolio, Germany (2013). [cited by applicant]
Lehner, M., et al., “Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection,” PLoS One 7:e31210, PLOS, United States (2012). [cited by applicant]
Li, L., and Chandrasegaran, S., “Alteration of the cleavage distance of Fok I restriction endonuclease by insertion mutagenesis,” Proc. Natl. Acad. Sci. USA 90(7):2764-2768, National Academy of Sciences, United States (… [cited by applicant]
Li, L., et al., “Functional domains in Fok I restriction endonuclease,” Proc. Natl. Acad. Sci. USA 89(10):4275-4279, National Academy of Sciences, United States (May 1992). [cited by applicant]
Lorenz, C., et al., “Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells,” Bioorg. Med. Chem. Lett. 14(19):4975-4977, Elsevier, Netherlands (Oct. 2004). [cited by applicant]
Louis, C.U., et al., “Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma,” Blood 118:6050-6056, American Society of Hematology, United States (2011). [cited by applicant]
Luens, K. M., et al., “Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin-cells with preserved ability to engraft SCID-hu … [cited by applicant]
Ma, M. Y., et al., “Nuclease-resistant external guide sequence-induced cleavage of target RNA by human ribonuclease P,” Antisense Nucleic Acid Drug Dev. 8(5):415-426, Mary Ann Liebert, Inc., United States (Oct. 1998). [cited by applicant]
Maher, J., “Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells,” ISRN Oncol. 2012:278093, Hindawi, United Kingdom (2012). [cited by applicant]
Maher, J., et al., “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor,” Nat. Biotech. 20:70-75, Springer Nature Ltd., Germany (2002). [cited by applicant]
Martinez, J., et al., “Single-stranded antisense siRNAs guide target RNA cleavage in RNAi,” Cell. 110:563-574, Cell Press, United States (2002). [cited by applicant]
McGuinness, R.P., et al., “Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor,” Hum. Gene Ther. 10:165-173, Mary Ann Liebert, Inc., United States (1999). [cited by applicant]
Meazza, R., et al., “Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy,” J. Biomed. & Biotechnol. 2011:861920, Hindawi, United Kingdom (2011). [cited by applicant]
Meier, R., et al., “Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging,” Magn. Reson. Med. 65:756-763, Wiley, United States (2011). [cited by applicant]
Mezzanzanica, D., et al., “Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells,” Cancer Gene Ther. 5:401-407, Springer Nature Ltd., Germ… [cited by applicant]
Michaud, A., et al., “IL-7 enhances survival of human CD56bright NK cells,” J. Immunotherapy 33:382-390, Lippincott Williams and Wilkins Ltd, United States (2010). [cited by applicant]
Miller, J. C., et al., “A TALE nuclease architecture for efficient genome editing,” Nat. Biotechnol. 29(2):143-148, Nature Publishing Group, United Kingdom (Feb. 2011). [cited by applicant]
Moon, E.K., et al., “Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor,” Clin. Cancer Res.… [cited by applicant]
Morgan, R.A., et al., “Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2,” Mol. Ther. 18:843-851, Cell Press, United States (201… [cited by applicant]
Morgan, R.A., et al., “Recognition of glioma stem cells by genetically modified T cellstargeting EGFRvIII and development of adoptive cell therapy for glioma,” Hum. Gene Ther. 23:1043-1053, Mary Ann Liebert, Inc., Unite… [cited by applicant]
Morgenroth, A., et al., “Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells,” Prostate 67:1121-1131, Wiley, United States (2007). [cited by applicant]
Moritz, D., et al., “Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells,” Proc. Natl. Acad. Sci. USA 91:4318-4322, National Academy of Sciences, United States (1994). [cited by applicant]
Muniappan, A., et al., “Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes,” Cancer Gene Ther. 7:128-134, Springer, Germany (2000). [cited by applicant]
Nakamura, Y., et al., “Codon usage tabulated from international DNA sequence databases: status for the year 2000,” Nucl. Acids Res. 28:292, Oxford University Press, United Kingdom (2000). [cited by applicant]
Napoli, C., et al., “Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans,” Plant Cell 2:279-289, American Society of Plant Biologists, United … [cited by applicant]
Niederman, T.J., et al., “Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors,” Proc. Natl. Acad. Sci. USA 99:7009-7014, National Academy of Sciences, United S… [cited by applicant]
Nishimura, H., et al., “Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor,” Immunity 11:141-151, Cell Press, United States (1999). [cited by applicant]
Noble, P. W., et al., “Optimizing a lupus autoantibody for targeted cancer therapy,” Cancer Res 75(11):2285-2291, American Association for Cancer Research, United States (Jun. 2015). [cited by applicant]
Nolan, K.F., et al., “Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA,” Clin. Cancer Res. 5:3928-3941, Amer… [cited by applicant]
Nyce, J. W., and Metzger, W. J., “DNA antisense therapy for asthma in an animal model,” Nature 385(6618):721-725, Nature Publishing Group, United Kingdom (Feb. 1997). [cited by applicant]
Nykanen, A., et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway,” Cell 107:309-321, Cell Press, United States (2001). [cited by applicant]
Oltersdorf, T., et al., “An inhibitor of Bcl-2 family proteins induces regression of solid tumours,” Nature 435:677-681, Nature Portfolio, Germany (2005). [cited by applicant]
Opferman, J.T., et al., “Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1,” Nature 426:671-676, Springer Nature Ltd., Germany (2003). [cited by applicant]
Park, J.J., et al., “B7—H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance,” Blood 116:1291-1298, American Society of Hematology, United States (2010). [cited by applicant]
Park, J.R., et al., “Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma,” Mol. Ther. 15:825-833, Cell Press, United States (2007). [cited by applicant]
Paulos, C.M., et al., “The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells,” Sci. Transl. Med. 2:55-78, American Association for the Advancement of Science, United States (2010). [cited by applicant]
Peinert, S., et al., “Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen,” Gene Ther. 17:678-686, Springer Nature Ltd., Germany (2010). [cited by applicant]
Pentcheva-Hoang, T., et al., “Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections,” Immunological Reviews 229:67-87, Nature P… [cited by applicant]
Pfeiffer, A., et al., “In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome,” EMBO Mol. Med. 10(11):e9158, European Molecular Biology Organization, Germany (201… [cited by applicant]
Pinthus, J.H., et al., “Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes,” J. Clin. Invest. 114:1774-1781, American Society for Clinical Investigation, United States (2004). [cited by applicant]
Porter, D.L., et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” N. Engl. J. Med. 365:725-733, Massachusetts Medical Society, United States (2011). [cited by applicant]
Pule, M.A., et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nat. Med. 14:1264-1270, Springer Nature Ltd., Germany … [cited by applicant]
Ramirez-Ortiz, Z., et al., “Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA” Infec. Immun. 76(5):2123-2129, American Society for Microbiology, United States (2008… [cited by applicant]
Ramos, C.A., et al., “Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy,” Expert Opin. Biol. Ther. 11(7):855-873, Taylor & Francis, United Kingdom (2011). [cited by applicant]
Rattray, Z., et al., “Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications,” Biochem Biophys Res Commun 496(3):858-864, Elsevier, Netherlands (Jan. 2018). [cited by applicant]
Rein-Heidenreich, L.R., et al., “Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis,” Cancer Immunol. Immunother. 51:417-423, Springer Science+Busine… [cited by applicant]
Ribas, A., et al., “Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma,” Clinical Cancer Research 15:6267-6276, American Association for Cancer Research, United States (2009). [cited by applicant]
Ricciardi, A. S., et al., “In utero nanoparticle delivery for site-specific genome editing,” Nat Commun 9(1):2481, Nature Publishing Group, United Kingdom (Jun. 2018). [cited by applicant]
Ritchie, D.S., et al., “Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia,” Mol. Ther. 21(11):2122-2129, Cell Press, United States (2013). [cited by applicant]
Robbins, R., “Gene therapy pioneer says the field is behind—and that delivery technology is embarrassing,” StatNews.com, Nov. 2019, accessed at https://www.statnews.com/2019/11/21/gene-therapy-pioneer-says-the-field-is-… [cited by applicant]
Robert, C., et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal of Medicine 372:320-330, Massachusetts Medical Society, United States (2015). [cited by applicant]
Rosenberg, S.A., et al., “Passive immunotherapy of cancer in animals and man,” Adv. Cancer Res. 25:323-388, Wolters Kluwer, Netherlands (1977). [cited by applicant]
Rossig, C., et al., “Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes,” Int. J. Cancer. 94:228-236, Wiley, United States (2001). [cited by applicant]
Rump, E. T., et al., “Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein,” Biochem Pharmacol 59(11):1407-14… [cited by applicant]
Sampson, J.S., et al., “Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma,” Semin Immunol. 20(5):267-275, Academic Press Inc., United States (2008). [cited by applicant]
Savoldo, B., et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” J. Clin. Invest. 121:1822-1826, American Society for Clinical Investigatio… [cited by applicant]
Savoldo, B., et al., “Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease,” Blood 110:2620-2630, American Society of … [cited by applicant]
Schuberth, P.C., et al., “Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma,” Gene Ther. 20:386-395, Springer Nature Ltd., Germany (2013). [cited by applicant]
Seow, Y., et al., “Biological gene delivery vehicles: beyond viral vectors,” Mol. Ther. 17(5):767-777, Cell Press, United States (2009). [cited by applicant]
Shaffer, D.R., et al., “T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies,” Blood 117:4304-4314, American Society of Hematology, United States (2011). [cited by applicant]
Smith, T.T., et al., “In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers,” Nat. Nanotechnol. 12(8):813-820, Nature Portfolio, Germany (2017). [cited by applicant]
Song, D.G., et al., “Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition,” Hum. Gene Ther. 24:295-305, Mary Ann Liebert, Inc., United States (2013). [cited by applicant]
Song, Y.C., et al., “Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions,” Eur. J. Immunol. 38:3178-3190, Wiley-VCH, Germany (2008). [cited by applicant]
Song, E., et al., “Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors,” Nat. Biotechnol. 23(6):709-717, Nature Publishing Group, United Kingdom (2005). [cited by applicant]
Soutschek, J., et al., “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs,” Nature 432(7014):173-178, Nature Publishing Group, United Kingdom (Nov. 2004). [cited by applicant]
Spear, P., et al., “Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF,” J. Immunol. 188:6389-6398, American Association of Immunologists, United Sta… [cited by applicant]
Spertini, F., et al., “Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis,” J. Rheumatol. 26(12):2602-2608, Journal of Rheumatol… [cited by applicant]
Spranger, S., et al., “Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment,”… [cited by applicant]
Stancovski, I., et al., “Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors,” J. Immunol. 151:6577-6582, , United States (1993). [cited by applicant]
Stepinski, J., et al., “Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG,” RNA 7:1468-1495, Cold Spring Harbor Laboratory Press , … [cited by applicant]
Sterchak, E.P., et al., “Uncharged stereoregular nucleic acid analogs. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages,” J. Organic Chem. 52(19):4202-4206, American Chemical Societ… [cited by applicant]
Tamada, K., et al., “Redirecting gene-modified T cells toward various cancer types using tagged antibodies,” Clin. Cancer Res. 18:6436-6445, American Association for Cancer Research, United States (2012). [cited by applicant]
Teng, M.W., et al., “Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes,” Hum. Gene. Ther. 15:699-708, Mary Ann Liebert, Inc., United States (2004). [cited by applicant]
Tettamanti, S., et al., “Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor,” Br. J. Haematol. 161:389-401, Wiley-Blackwell Publishing … [cited by applicant]
Till, B.J., et al., “Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells,” Blood 112:2261-2271, American Society of Hematology, U… [cited by applicant]
Tivol, E.A., et al., “Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4,” Immunity 3:541-547 , Cell Press, United States… [cited by applicant]
Topalian, S.L., et al., “Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab,” J. Clin. Oncol. 32:1020-1030, American Society of Clinical Oncology,, United Stat… [cited by applicant]
Topalian, S.L., et al.,“ Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” New England Journal of Medicine 366:2443-2454, Massachusetts Medical Society, United States (2012). [cited by applicant]
Turchick, A., et al., “Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells,” Oncotarget. 10(13):1272-1283, Impact Journals, United Kingdom (2019). [cited by applicant]
Turchick, A., et al., “A cell-penetrating antibody inhibits human RAD51 via direct binding,” Nucleic Acids Res 45(20):11782-11799, Oxford University Press, United Kingdom (Nov. 2017). [cited by applicant]
Twyman-Saint Victor, C., et al., “Radiation and dual checkpoint blockade activate non- redundant immune mechanisms in cancer,” Nature 520:373-377, Nature Publishing Group, United Kingdom (2015). [cited by applicant]
Ui-Tei, K., et al., “Sensitive assay of RNA interference in Drosophila and Chinese hamster cultured cells using firefly luciferase gene as target,” FEBS Lett. 479:79-82, Wiley, United States (2000). [cited by applicant]
Uniprotkb, “B2CL1_Human,” Accession No. Q07817, accessed at https://www.uniprot.org/uniprotkb/Q07817/entry, accessed on Jun. 30, 2022, 17 pages. [cited by applicant]
Uniprotkb, “IL15_Human,” Accession No. P40933, accessed at https://www.uniprot.org/uniprotkb/P40933/entry, on Jun. 30, 2022, 6 pages. [cited by applicant]
Uniprotkb, “IL2_Human,” Accession No. P60568, accessed at https://www.uniprot.org/uniprotkb/P60568/entry, accessed on Jun. 30, 2022, 9 pages. [cited by applicant]
Uniprotkb, “IL7_Human,” Accession No. P13232, accessed at https://www.uniprot.org/uniprotkb/P13232/entry, on Jun. 30, 2022, 6 pages. [cited by applicant]
Uniprotkb, “MCL1_Human,” Accession No. Q07820, accessed at https://www.uniprot.org/uniprotkb/Q07820/entry, on Nov. 3, 2022, 12 pages. [cited by applicant]
Urbanska, K., et al., “A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor,” Cancer Res. 72(7):1844-1852, American Association for Cancer Research, United States (201… [cited by applicant]
Vera, J., et al., “T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108:3890-3897, American Society of Hematology, Unite… [cited by applicant]
Vollmer, J. and Krieg, A.M., “Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists,” Adv. Drug Del. Rev. 61(3):195-204, Elsevier, Netherlands (2009). [cited by applicant]
Wang, J., et al., “Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes,” Mol. Ther. 9:577-586, Cell Press, United States (2004). [cited by applicant]
Wang, J., et al., “Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains,” Hum. Gene Ther. 18:712-725, Mary Ann Liebert, Inc.,… [cited by applicant]
Wang, S., et al., “Immunobiology of cancer therapies targeting CD137 and B7—H1/PD-1 cosignal pathways,” Curr. Top. Microbial Immunol. 344:245-267, Springer, Germany (2011). [cited by applicant]
Waterhouse, P., et al., “Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4,” Science 270:985-988, American Association for the Advancement of Science, United States (1995). [cited by applicant]
Weijtens, M.E., et al., “Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules,” Int. J. Canc. 77:181-187, Wiley, United States (1998). [cited by applicant]
Weiner, G.L., et al., “Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization,” PNAS USA 94(20):10833-10837, National Academy of Sciences, United… [cited by applicant]
Weisbart, R.H., et al., “An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications,” J. Autoimmun. 11(5):539-546, Elsevier, Netherlands (Oct. 1998). [cited by applicant]
Weisbart, R.H., et al., “Antibody-mediated transduction of p53 selectively kills cancer cells,” Int. J. Oncol. 25(6):1867-1873, Spandidos Publications, Greece (Dec. 2004). [cited by applicant]
Weisbart, R.H., et al., “DNA-dependent targeting of cell nuclei by a lupus autoantibody,” Sci. Rep. 5:12022, Nature Publishing Group, United Kingdom (Jul. 2015). [cited by applicant]
Weisbart, R.H., et al., “An intracellular delivery vehicle for protein transduction of micro-dystrophin,” J. Drug Target 13(2):81-87, Informa, United Kingdom (2005). [cited by applicant]
Weisbart, R.H., et al., “Novel Protein Transfection of Primary Rat Cortical Neurons Using an Antibody That Penetrates Living Cells,” J, Immunol. 164(11):6020-6026, American Association of Immunologists, United States (2… [cited by applicant]
Weisbart, R.H., et al., “A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus,” J. Immunol. 144(7):2653-2658, American Association of Immunologists, United St… [cited by applicant]
Weisbart, R.H., et al., “Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells,” Cancer Lett. 195(2):211-219, Elsevier, Netherlands (200… [cited by applicant]
Weisbart, R.H., et al., “Beneficial Effects Of Oral Immunoglobulin In Rheumatoid Arthritis,” J. Clin. Rheumatol. 1(2):135, Lippincott Williams &Wilkins, United States (1995). [cited by applicant]
Weisbart, R.H., et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that minds myosin lib,” Mol. Immunol. 39(13):783-789, Pergamon Press, United Kingdom (2003). [cited by applicant]
Weisbart, R.H., et al., “A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets,” Mol. Cancer. Ther. 11(10):2169-2173, American Association for Cancer Research Inc., United States (20… [cited by applicant]
Weisbart, R.H., et al., “Construction and expression of a bispecific single-chain antibody that penterates mutant p53 colon cancer cells and binds p53,” Int. J. Oncol. 25(4):1113-1118, Spandidos Publications, Greece (20… [cited by applicant]
Weising, K., et al., “Foreign genes in plants: transfer, structure, expression, and applications,” Ann. Rev. Genetics. 22:421, Annual Reviews, United States (1988). [cited by applicant]
Westwood, J.A., et al., “Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice,” Proc. Natl. Acad. Sci. USA. 102:19051-19056, National Academy… [cited by applicant]
Wherry, E.J., et al., “T cell exhaustion,” Nat. Immunol. 12:492-499, Nature Portfolio, Germany (2011). [cited by applicant]
Wilkie, S., et al., “Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor,” J. Immunol. 180:4901-4909, American Association of Immunologists, United States (2008). [cited by applicant]
Willemsen, R.A., et al., “A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes,” Gene Ther. 8:1601-1608, Springer Nature Ltd., G… [cited by applicant]
Willemsen, R.A., et al., “T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production,” J. Immunol. 174:7853-7858, American Ass… [cited by applicant]
Wing, K., et al., “CTLA-4 control over Foxp3+ regulatory T cell function” Science 322:271-275, American Association for the Advancement of Science, United States (2008). [cited by applicant]
Yaghoubi, S.S., et al., “Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG Pet in a patient with glioma,” Nat. Clin. Pract. Oncol. 6:53-58, Nature Portfolio, Germany (2009). [cited by applicant]
Yanase, K., et al., “Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1,” J. Clin. Invest. 100:25-31, American Society for Clinical Investigation, United States (1997). [cited by applicant]
Yu, P., et al., “Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model,” Clin Cancer Res. 16:6019-6028… [cited by applicant]
Yun, C.O., et al., “Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors,” Neoplasia 2:449-459, Elsevier, Netherlands (2000). [cited by applicant]
Zack, D. J., et al., “DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus,” J. Immunol. 154(4):1987-1994, American Association of Immunologists, United States (Feb… [cited by applicant]
Zack, D. J., et al., “Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody,” J. Immunol. 157(5):2082-2088, American Association of Immunologists, United States (Sep. 1996… [cited by applicant]
Zack, D. J., et al., “Novel structural features of autoantibodies in murine lupus: a possible superantigen binding site?,” Immunol. Cell Biol. 72(6):513-520, John Wiley & Sons, Inc., United States (Dec. 1994). [cited by applicant]
Zetsche, C., et al., “Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system,” Cell 163(3):759-771, Cell Press, United States (2015). [cited by applicant]
Zhan, X., et al., “Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats,” Stroke. 41(3):538-543, Lippincot Williams & Wilkins, United States (2010). [cited by applicant]
Zhang, H,, et al., “Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells,” Nature Medicine 11:1238-1243, Springer Nature Ltd., Germany (2005). [cited by applicant]
Zhang, T., et al., “Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy,” Blood 106:1544-1551, American Society of Hematology, United States (2005). [cited by applicant]
Zhang, X., et al., “Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING,” Mol. Cell. 51(2):226-235, Cell Press, United States (2013). [cited by applicant]
Zhao, Y., et al., “A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity” J. Immunol. 183:5563-5574, American Associati… [cited by applicant]
Zhou, J., et al., “Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery,” Nat. Mater. 11(1):82-90, Nature Publishing Group, United Kingdom (Dec. 2011). [cited by applicant]
Zielke, H. R., and Littlefield, J. W., “Repetitive synchronization of human lymphoblast cultures with excess thymidine,” Methods Cell Biol. 8(0):107-121, Elsevier, Netherlands (1974). [cited by applicant]
Zou, W., et al., “Inhibitory B7-family molecules in the tumour microenvironment” Nat. Rev. Immunol. 8:467-477, Nature Portfolio, Germany (2008). [cited by applicant]
Hwu, P., et al., “Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain,” J Exp Med. Jul. 1, 1993;178(1):361-6. [cited by applicant]
An, D.S., et al., “Optimization and Functional Effects of Stable Short Hairpin RNA Expression in Primary Human Lymphocytes via Lentiviral Vectors,” Molecular Therapy 14(4):494-504, Elsevier, Netherlands (Oct. 2006). [cited by applicant]
Byles, V., et al., “Aberrant Cytoplasm Localization and Protein Stability of SIRT1 is Regulated by PI3K/IGF-IR Signaling in Human Cancer Cells,” International Journal of Biological Sciences 6(6):599-612, Lvyspring Inter… [cited by applicant]